TY - JOUR
T1 - Breast implant-associated anaplastic large cell lymphoma
T2 - a review
AU - Quesada, Andrés E.
AU - Medeiros, L. Jeffrey
AU - Clemens, Mark W.
AU - Ferrufino-Schmidt, Maria C.
AU - Pina-Oviedo, Sergio
AU - Miranda, Roberto N.
N1 - Publisher Copyright:
© 2018, United States & Canadian Academy of Pathology.
PY - 2019/2/1
Y1 - 2019/2/1
N2 - Breast implant-associated anaplastic large cell lymphoma is a newly recognized provisional entity in the 2017 revision of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. It is an uncommon, slow growing T-cell lymphoma with morphology and immunophenotype similar to anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. However, the presentation and treatment are unique. Breast implant-associated anaplastic large cell lymphoma often presents as a unilateral effusion confined to the capsule of a textured-surface breast implant, a median time of 9 years after the initial implants have been placed. Although it follows an indolent clinical course, breast implant-associated anaplastic large cell lymphoma has the potential to form a mass, to invade locally through the capsule into breast parenchyma or soft tissue and/or to spread to regional lymph nodes. In most cases, an explantation with a complete capsulectomy removing all disease, without chemotherapy is considered to be curative and confers an excellent event free and overall survival. Here we provide a comprehensive review of breast implant-associated anaplastic large cell lymphoma, including history, epidemiology, clinical features, imaging and pathology findings, pathologic handling, pathogenic mechanisms, model for progression, therapy and outcomes as well as an analysis of causality between breast implants and anaplastic large cell lymphoma.
AB - Breast implant-associated anaplastic large cell lymphoma is a newly recognized provisional entity in the 2017 revision of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues. It is an uncommon, slow growing T-cell lymphoma with morphology and immunophenotype similar to anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. However, the presentation and treatment are unique. Breast implant-associated anaplastic large cell lymphoma often presents as a unilateral effusion confined to the capsule of a textured-surface breast implant, a median time of 9 years after the initial implants have been placed. Although it follows an indolent clinical course, breast implant-associated anaplastic large cell lymphoma has the potential to form a mass, to invade locally through the capsule into breast parenchyma or soft tissue and/or to spread to regional lymph nodes. In most cases, an explantation with a complete capsulectomy removing all disease, without chemotherapy is considered to be curative and confers an excellent event free and overall survival. Here we provide a comprehensive review of breast implant-associated anaplastic large cell lymphoma, including history, epidemiology, clinical features, imaging and pathology findings, pathologic handling, pathogenic mechanisms, model for progression, therapy and outcomes as well as an analysis of causality between breast implants and anaplastic large cell lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=85053500104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053500104&partnerID=8YFLogxK
U2 - 10.1038/s41379-018-0134-3
DO - 10.1038/s41379-018-0134-3
M3 - Review article
C2 - 30206414
AN - SCOPUS:85053500104
SN - 0893-3952
VL - 32
SP - 166
EP - 188
JO - Modern Pathology
JF - Modern Pathology
IS - 2
ER -